Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CEO Sells 562,345 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 562,345 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $50.93, for a total transaction of $28,640,230.85. Following the transaction, the chief executive officer now directly owns 9,457,283 shares in the company, valued at approximately $481,659,423.19. The trade was a 5.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Tempus AI Stock Up 0.5 %

Tempus AI stock traded up $0.24 during midday trading on Friday, reaching $49.10. The stock had a trading volume of 9,329,504 shares, compared to its average volume of 4,780,767. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company has a fifty day moving average price of $54.02 and a two-hundred day moving average price of $52.54. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEM. Operose Advisors LLC purchased a new position in Tempus AI in the fourth quarter valued at about $25,000. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI during the 3rd quarter valued at $30,000. Farther Finance Advisors LLC purchased a new stake in shares of Tempus AI in the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC boosted its holdings in Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares during the period. Finally, NewEdge Advisors LLC bought a new position in shares of Tempus AI in the fourth quarter worth approximately $49,000. 24.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on TEM shares. Needham & Company LLC boosted their price target on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. William Blair reiterated a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the company from $45.00 to $65.00 in a report on Monday, November 11th. Morgan Stanley boosted their target price on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Wolfe Research cut shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and a consensus target price of $61.18.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.